相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
相关阅读
从原料到标记,打造属于中国自己的流式抗体品牌推荐!临床医学研究优质期刊,覆盖29个领域五大应用案例:Mustang Q 膜层析应用全解析1 个小工具,一次性搞定流程图、质粒图谱和信号通路图- 详细信息
- 文献和实验
- 技术资料
- 保存条件:
Powder:2-8℃,2 years;Insolvent(母液):-20℃,6 months;-80℃,1 year
- 保质期:
Powder:2-8℃,2 years;Insolvent(母液):-20℃,6 months;-80℃,1 year
- 英文名:
SU5205
- 库存:
999
- 供应商:
北京索莱宝科技有限公司
- CAS号:
3476-86-6
- 规格:
50mg/100mg
| 规格: | 50mg | 产品价格: | ¥490.00 |
|---|---|---|---|
| 规格: | 100mg | 产品价格: | ¥790.00 |
| CAS | 3476-86-6 |
| 英文名称 | SU5205 |
| 分子式 | C15H10FNO |
| 分子量 | 239.25 |
| 规格 | 50mg ; 100mg |
| 溶解性 | Soluble in Water ≥10mg/mL(Need ultrasonic) |
| 纯度 | ≥98% |
| 外观(性状) | White to yellow Solid |
| 储存条件 | Powder:2-8℃,2 years;Insolvent(母液):-20℃,6 months;-80℃,1 year |
| 运输条件 | 冷藏运输 |
| MDL | MFCD00435356 |
| SMILES | C1=CC=C2C(=C1)C(=CC3=CC=C(C=C3)F)C(=O)N2 |
| InChIKey | QIERHADIMMFZNE-LCYFTJDESA-N |
| InChI | InChI=1S/C15H10FNO/c16-11-7-5-10(6-8-11)9-13-12-3-1-2-4-14(12)17-15(13)18/h1-9H,(H,17,18)/b13-9- |
| PubChem CID | 5398217 |
| 靶点 | VEGFR |
| 通路 | Angiogenesis;Protein Tyrosine Kinase/RTK |
| 背景说明 | SU5205是VEGFR2 (FLK-1) 的抑制剂。 |
| 单位 | 瓶 |
| 表格1 | |*|1mg|5mg|10mg|$$|1mM|4.1797mL|20.8986mL|41.7973mL|$$|5mM|0.8359mL|4.1797mL|8.3595mL|$$|10mM|0.418mL|2.0899mL|4.1797mL| |

风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Fabrication of Polydimethylsiloxane Microfluidics Using SU-8 Molds
We detail the widely prevalent technique of polydimethylsiloxane (PDMS) molding using SU-8 for creating microfluidic chambers and channels. Although other techniques such as injection molding are more apt for mass manufacturing and cost
Rapid Prototyping of PDMS Devices Using SU-8 Lithography
This protocol describes the fabrication of single and multi-layer SU-8 microstructures for generating microfluidic devices via PDMS (polymethyldisiloxane) casting. SU-8 is a negative, thick-film, epoxy based photoresist
with FGF signaling by treating embryos with SU5402 (Calbiochem), a FGF receptor inhibitor. We observed craniofacial deformities and delayed maturation in embryos treated with SU5402. this indicates that FGF signaling is required for cranifacial formation
技术资料暂无技术资料 索取技术资料











